Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line and First-line Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome Intervention: Drug: OPN-305 Sponsors: Opsona Therapeutics Ltd.; M.D. Anderson Cancer Center; Montefiore Medical Center; H. Lee Moffitt Cancer Center and Research Institute; New York Presbyterian Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials